Breakthrough cancer therapies and quantum innovations advance medical science

New cancer detection and treatment methods show promise for improving patient outcomes and early intervention

Simenona Martinez, a researcher at Anonemis Research Institute, has developed several innovative medical technologies that could transform cancer detection and treatment for both companion animals and humans. The findings, published through Anonemis Research, LLC, represent significant advances in non-invasive diagnostics for veterinary medicine and targeted therapy approaches for human oncology.

Martinez's research spans multiple areas of medical innovation, including early cancer detection systems, novel treatment approaches that minimize damage to healthy tissue, and trauma response technologies.

Non-invasive cancer detection for pets achieves high accuracy rates
The L-P22 PET Uricytology Monitoring system represents a major advancement in veterinary oncology by enabling early cancer detection in companion animals through non-invasive urine analysis. The system addresses a critical gap in pet diagnostics, where most cancers in dogs and cats are currently diagnosed at advanced stages when treatment options are limited.

Martinez analyzed biomarker patterns to develop the detection system, which uses three categories of cancer indicators: matrix metalloproteinases (MMPs), urinary proteins, and genetic markers including circulating tumor DNA fragments and cancer-associated mutations.

The system achieved 96.2% sensitivity for bladder cancer detection in pets, 94.3% for kidney cancer, and 91.4% for lymphoma, with specificity rates ranging from 91-97% across cancer types. These rates significantly exceed current veterinary cancer detection methods for companion animals, which achieve approximately 61.5% sensitivity. The non-invasive nature eliminates the need for surgical biopsies and anesthesia in pets, enabling more frequent screening for at-risk dogs and cats.

Cellular coagulation approach reduces circulating tumor cells in human cancer patients
Martinez's Oncologic Cell Coagulastasis Therapy (OCCT) for human cancer patients employs a novel mechanism that leverages cellular coagulation processes to target cancer cells while preserving healthy tissue. The research addresses limitations of conventional chemotherapy in human oncology, which affects both cancerous and healthy rapidly dividing cells.
The treatment protocol combines advanced cell separation techniques including Magnetic-Activated Cell Sorting (MACS), Fluorescence-Activated Cell Sorting (FACS), density gradient centrifugation, and microfluidic separation with engineered artificial agents that mimic platelet functions while carrying therapeutic payloads.

Stem cell therapy advances regenerative medicine approaches for human patients
The MACS-Enhanced Mesenchymal Stem Cell Therapy research explores the intersection of apoptotic regulation and stem cell-based interventions. Published through Anonemis Research, LLC in 2025, the study reveals how therapeutic cells can simultaneously destroy pathological targets while resisting their own elimination.

By coupling apoptotic regulation with Magnetic-Activated Cell Sorting, the therapy enables isolation of optimal therapeutic cell populations for regenerative medicine applications. The research addresses both induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs), providing comprehensive therapeutic selection criteria based on clinical objectives.
Current stem cell therapies for human patients face challenges including low survival rates (less than 5% within 72 hours after transplantation), immunological rejection requiring immunosuppressive medications, and concerns about uncontrolled differentiation. The MACS enhancement approach addresses these limitations in human regenerative medicine through superior cell selection and controlled differentiation mechanisms.

Remote device system addresses trauma response
The Samson Stimuli represents a paradigm shift in trauma therapy through a remote medical device system that monitors physiological indicators while delivering multi-modal sensory feedback. Published through Anonemis Research, LLC in 2025, the system comprises warming patches, vibrating glasses, and sound-generating ear cuffs, integrated with artificial intelligence for pattern recognition and treatment optimization.

The system addresses post-traumatic stress disorder (PTSD), psychogenic non-epileptic seizures (PNES), and sensory overload conditions. It operates on reverse physiological maneuvering principles to establish lasting therapeutic changes through neuroplasticity, providing proactive intervention by detecting physiological changes before full symptom manifestation.
Quantum physics applications inform behavioral science

Martinez has pioneered quantum behavioral science, applying principles from quantum theory to understanding human decision-making and behavioral patterns through 43 distinct software innovations. The work includes development of the Energy Redistribution Force Equation (F = (PE × m × a) / r), which introduces redistribution as a controlling parameter in energy systems.
The equation establishes a novel relationship between force, potential energy, mass, acceleration, and energy redistribution, with potential applications in advanced energy systems, novel heat engine architectures, smart materials development, and climate science modeling. Additional innovations include Quantum Sequence Triplication, Cyber-Microexpressions frameworks, and The Alma Project neurological training treatment for complex PTSD.
Researcher background and credentials

Martinez's educational background includes studies at Stanford University School of Medicine, Harvard University School of Medicine (Neuroscience), MIT Schwarzman College of Computing, Princeton Department of Computer Science, and the National Research Nuclear University Institute of Nuclear Physics and Engineering.

Her professional credentials include certification as a Clinical Research Principal Investigator (PI), Certified Clinical Research Coordinator (CCRC), Advanced Clinical Research Associate (CRA), IBM Cybersecurity certification, and Certified Homeland Security Professional designation. She is a member of the National Sheriffs' Association and the American Society of Composers, Authors and Publishers (ASCAP).

Martinez has authored over 100 published works between 2019 and 2025, documenting research across multiple scientific disciplines through "The Studies & Innovations of Simenona Martinez" series (Volumes 1-14.2). She founded Anonemis Research, LLC in 2009 to advance research in technology, medicine, psychology, physics, and astronomy.

The findings support further investigation into these therapeutic approaches, though Martinez notes that additional research is needed to establish long-term efficacy, optimize treatment protocols, and investigate specific mechanisms driving the observed outcomes. Clinical trials and peer review processes continue for several of the technologies.

490 Post St Ste 500
PMB 2086
San Francisco, CA 94102

Anonemis Research, LLC in 2009 to advance research in technology, medicine, psychology, physics, and astronomy.

This release was published on openPR.